Merck will lay off 6,000, reducing workforce by 8% fiercepharma.com/pharma/merc…

Zakaj Slovenija cinca s prepovedjo solarijev za mladoletne dnevnik.si/novice/slovenija/…

🧵#pohvalanadan Če boste kdaj potrebovali odzivnega & prijaznega serviserja za belo tehniko (razen kuhalne tehnike) v Ljubljani. Že tretjič me je pronto rešil Servis Lamovec. V soboto sem celo pozabila, da so prazniki, a je vseeno odgovoril v eni uri, danes zjutraj pa že prišel.

Quetiapine outperformed lithium augmentation, with similar tolerability, in 1-yr RCT of treatment resistant depression: ncbi.nlm.nih.gov/pubmed/4011… Surprised? Well, quetiapine has unique anxiety/sleep benefits, and approached esketamine's efficacy in 32-wk trial.

💉Accelerated Infusion of Nivolumab and Pembrolizumab @EORTC ✅Infusion in 10 minutes is safe 👉doi.org/10.1016/j.ejca.2025.… @OncoAlert @realbowtiedoc #cancer #oncology #MedX

Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis fiercepharma.com/pharma/nova…

📢 Our comprehensive review on post-progression treatment strategies after CDK4/6 inhibitor in HR /HER2− MBC is now published in Cancer Treatment Reviews. Grateful to @DenizCanGuven1 and @aksoysercan for their invaluable mentorship and support 🙏🏻 👉doi.org/10.1016/j.ctrv.2025.…

Catalyst: after $AZN's SERD success, $RHHBY looks to the front line. Via @ApexOnco -> oncologypipeline.com/apexonc… $OLMA $ARVN

Excellent review - Management of hepatocellular cancer ascopubs.org/doi/10.1200/OP-… @JCOOP_ASCO @OncoAlert @RyanNipp @ASCO

Brexpiprazole-sertraline combo worked better than either alone (or placebo) in new 4-arm trial of PTSD: pubmed.ncbi.nlm.nih.gov/4000… In mice, brexpiprazole sharpened memory for real threats, while reducing the overgeneralized threat-response in #PTSD: pubmed.ncbi.nlm.nih.gov/3281…

Viewpoint: The growing use of immune checkpoint inhibitors in cancer treatment brings significant therapeutic benefits but also long-term immune-related adverse effects. ja.ma/4gYT8NR

Dejte mal svoje sindikaliste zdrmat; mi smo dobil še razlike od diskriminatornih božičnic nakazane. Pa ni blo to mal dnarja.

BeiGene fleshes out global ambition as Brukinsa surpasses AstraZeneca's Calquence in quarterly sales fiercepharma.com/pharma/beig…

Oncologists on X are buzzing about the SERENA-6 trial. Camizestrant demonstrated highly statistically significant and clinically meaningful improvement in progression-free survival in 1st-line advanced HR-positive breast cancer with an emergent ESR1 tumour mutation in SERENA-6 Phase III trial. #LARVOL #SERENA6 #Oncology #CancerResearch #CancerData #ClinicalTrials #OncologyDevelopments #Camizestrant #BreastCancer Connect with the oncologists who are buzzing about the SERENA-6 trial on X: @stolaney1 | @PTarantinoMD | @jhaveri_komal | @ErikaHamilton9 | @BianchiniGP | @SuyogCancer

The #SERENA6 phase 3 trial is positive: a switch to camizestrant CDK4/6i (vs continuation of AI CDK4/6i) upon emergence of ESR1 mutations led to a significant improvement in PFS. PFS2 and OS, which will be key to interpret the results, remain immature. astrazeneca.com/media-centre…

Interesting commentary on one of the most relevant and debated recent studies in breast oncology: SONIA. Are the results compelling enough to consider a delayed administration of CDK4/6-inhibitors for HR /HER2- MBC? nature.com/articles/s41571-0…

Finally out. This work is the result of a successful collaborative effort. Thanks to all contributors!

Nikoli se nič ne spremeni? Dokler se ne. Vesela sem, ker je moja mama zdaj taka zanesenjakinja in kar poka od optimizma in energije. Po vseh letih depresivnih pogovorov, kako je vse strašno in kako se nič ne da. Piše Ivana Djilas, pisateljica. buff.ly/3COjioC

New High Blood Pressure Drug 1️⃣ Between 1950 and the mid-1960s, eight new classes of medication were first used. 2️⃣ The licensing of aprocitentan in 2024 represents the first new class of antihypertensive agent to become available since 2007 3️⃣ Aprocitentan, a new BP drug, is the first in almost 20 years. It helps manage uncontrolled hypertension when other treatments fail. 4️⃣ Their high initial cost makes them unlikely as first-line therapies, but their novel mechanisms offer added BP-lowering benefits alongside existing treatments. 5️⃣ Future treatments target angiotensin, aldosterone, and mineralocorticoids. These could offer better BP control with fewer side effects. @NutritionMadeS3 @theproof @DrNadolsky @DrKarlNadolsky @drmatthewnagra @maciejbanach @drpablocorral @SABOURETCardio @pnatarajanmd @DBellardoMD Review link: nature.com/articles/s41569-0…

Low-dose semaglutide reduced alcohol craving and consumption in adults with alcohol use disorder. ja.ma/3COtptq